Physicians' Academy for Cardiovascular Education

Diabetes & CVD

Diabetes type II confers an increased CVD risk. Recent scientific developments have yielded antidiabetic agents that positively impact CV risk in diabetic patients. Follow the latest insights into the close link between diabetes and CVD.

SGLT2i reduces outcomes in HFmrEF, HFpEF regardless of glycemic status

3' education - Sep. 22, 2022 - Prof. Pardeep Jhund, MD, PhD

Consistent beneficial effect with GLP-1RA across broad range of kidney function and kidney damage

3' education - Sep. 21, 2022

SGLT2i improves outcomes in HFpEF and HFmrEF

3' education - Aug. 27, 2022 - Prof. Scott Solomon, MD

Totality of evidence of SGLT2 inhibition in HF

3' education - Aug. 27, 2022 - Muthiah Vaduganathan, MD

All patients with HF regardless of EF benefit from SGLT2i

3' education - Aug. 27, 2022 - Prof. Pardeep Jhund, MD, PhD

Discussion - When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options

10' education - July 21, 2022

Expanding evidence on SGLT2i: Where are we now and what can we expect?

10' education - July 21, 2022 - Prof. Scott Solomon, MD

Triglycerides most commonly a marker of ectopic fat accumulation

5' education - July 20, 2022 - Prof. Naveed Sattar, MD, PhD

Primary care as gatekeeper in CKD and the need for collaboration with nephrologists

10' education - July 13, 2022 - Prof. Kamlesh Khunti, MD, PhD

Discussion - Preventing CKD in patients with diabetes - Exploring the current and future role of GLP-1RA

10' education - July 6, 2022 - Prof. Johannes Mann, MD, prof. Filip Knop, MD, PhD, and prof. Katherine Tuttle, MD

Why is early screening and risk identification of CKD in diabetes important?

10' education - July 6, 2022 - Rikke Borg, MD, PhD

Clinical dialogue: Lowering ASCVD risk in a patient with T2DM and obesity

15' education - July 5, 2022 - Prof. Nikolaus Marx, MD and Adie Viljoen, MD

Benefits and evolving insights on SGLT2i in the spectrum of LVEF

10' education - June 29, 2022 - Prof. Carolyn Lam, MD, PhD

Barriers for preventing CKD in patients with diabetes

10' education - June 28, 2022 - Prof. Christoph Wanner, MD

Clinical dialogue: CV risk in diabetes

15' education - June 22, 2022 - Prof. Nikolaus Marx, MD and Michael Lehrke, MD

The clinical challenges of initiating guideline recommended therapy in HF

10' education - June 21, 2022 - Prof. John McMurray, MD

Which patients with CKD and diabetes will benefit from management with GLP-1RA?

10' education - June 13, 2022 - Prof. Katherine Tuttle, MD

What is relevant for nephrology with regard to GLP-1RA in CVD?

10' education - June 10, 2022 - Prof. Filip Knop, MD, PhD

Cardiorenal effects of nonsteroidal MRAs in patients with CKD and T2DM

10' education - June 7, 2022 - Eugene E. Wright, Jr., MD, Jolanta Małyszko, MD, PhD and María José Soler, MD, PhD

GLP-1RA as new treatment option on the horizon for obesity

3' education - May 31, 2022 - Prof. Ulrich Laufs, MD, PhD

New insights and guidelines for the management of CKD and diabetes

10' education - May 31, 2022 - Prof. Johannes Mann, MD

Wide distribution of CVD-free life-years gained with GLP-1RA

5' education - Mar. 21, 2022 - Jan Westerink, MD, PhD

Role of a non-steroidal MRA in the treatment spectrum of patients with T2DM and CKD

10' education - Feb. 8, 2022 - Prof. Peter Rossing, MD, prof. Gerasimos Filippatos, MD and prof. Matthew Weir, MD

Rethinking responsibilities in the prevention and management of cardiometabolic disease

10' education - Dec. 7, 2021 - Prof. Stephan Jacob, MD

What is the effect of low-dose aspirin on dementia risk in T2DM?

3' education - Nov. 16, 2021 - Prof. Jane Armitage

Interpreting findings of studies on a non-steroidal MRA in T2DM and CKD

10' education - Nov. 9, 2021 - Prof. George Bakris, MD, prof. Betram Pitt, MD and prof. Rajiv Agarwal, MD

Symposium on the role of SGLT2i in tackling cardiorenal risk in diabetes

15' education - Oct. 28, 2021 - Prof. Melanie Davies, MD and prof. Nikolaus Marx, MD - Online CME

Dialogue on how to overcome clinical inertia with regard to SGLT2i

10' education - Oct. 28, 2021 - Prof. Melanie Davies, MD and prof. Nikolaus Marx, MD - Online CME

SGLT2i: Overview of recent trials and guideline recommendations

10' education - Oct. 28, 2021 - Prof. Nikolaus Marx, MD - Online CME

Introduction on tackling cardiorenal risk in diabetes

10' education - Oct. 28, 2021 - Prof. Melanie Davies, MD - Online CME

SGLT2i reduces outcomes in HFmrEF, HFpEF regardless of glycemic status

3' education - Sep. 22, 2022 - Prof. Pardeep Jhund, MD, PhD

EASD 2022 "Any patient that has HFmrEF or HFpEF is going to benefit from dapaglifozin regardless of glycemic status and regardless of background diabetes therapy", says Prof. Jhund.

Reduced muscle fat infiltration in anterior thigh muscle with GLP-1RA in overweight or obesity

News - Sep. 22, 2022

EASD 2022 A prespecified secondary analysis was performed to investigate whether muscle fat infiltration -associated with increased risk of HF- can be modified by treatment with liraglutide in patients with overweight or obesity.

Effect of SGLT2i on shifts in KDIGO CKD risk groups in T2DM patients

News - Sep. 22, 2022

EASD 2022 A post-hoc analysis of EMPA-REG OUTCOME examined the effect of empagliflozin on changes in risk of progression to ESKD by assessing worsening and improvement in KDIGO risk groups.

Pilot study suggests association of sodium and protein intake with early GFR dip after SGLT2i initiation

News - Sep. 21, 2022

EASD 2022 It is not known whether a higher intake of sodium and protein may lead to a higher extent of early dip in GFR in T2DM patients who started an SGLT2 inhibitor. A pilot study was undertaken with 28 subjects.

Consistent beneficial effect with GLP-1RA across broad range of kidney function and kidney damage

3' education - Sep. 21, 2022
**EASD 2022** A post hoc analysis showed that semaglutide reduces CV risk across all strata of kidney function and kidney damage in patients with T2DM who are at high CV risk.

EASD 2022 A post hoc analysis showed that semaglutide reduces CV risk across all strata of kidney function and kidney damage in patients with T2DM who are at high CV risk.

GLP-1RA consistently reduces risk of MACE across kidney function subgroups

News - Sep. 21, 2022

EASD 2022 This pooled post hoc analysis of SUSTAIN 6 and PIONEER 6 showed that that semaglutide consistently reduced the risk of MACE across eGFR and UACR subgroups in patients with T2DM who are at high CV risk.

Relationships of CRP and C-peptide with CV events and all-cause mortality in new onset T2DM

News - Sep. 21, 2022

EASD 2022 In patients with new onset T2DM in the DD2 cohort, high CRP was a better marker of all-cause mortality than future CV events, whereas high C-peptide was a better marker of increased CV risk.

Effects of nonsteroidal MRA on mortality in patients with CKD and T2DM

News - Aug. 30, 2022

ESC 2022 A prespecified exploratory FIDELITY subanalysis investigated the causes of death in patients with CKD and T2DM who were either treated with finerenone or placebo.

SGLT2i improves outcomes in HFpEF and HFmrEF

3' education - Aug. 27, 2022 - Prof. Scott Solomon, MD
**ESC 2022** Prof. Solomon summarizes the results of the DELIVER trial. “We believe that these data support the use of SGLT2i as foundational therapy in patients with HF, regardless of care setting or ejection fraction” said Prof. Solomon.

ESC 2022 Prof. Solomon summarizes the results of the DELIVER trial. “We believe that these data support the use of SGLT2i as foundational therapy in patients with HF, regardless of care setting or ejection fraction” said Prof. Solomon.

SGLT2i reduces primary endpoint of CV death or worsening HF in HFmrEF and HFpEF

News - Aug. 27, 2022

ESC 2022 The DELIVER trial shows that dapagliflozin reduced the risk of CV death or worsening HF in patients with HFmrEF or HFpEF, with no attenuation of treatment benefit in patients with the highest EF.

Improved outcomes with SGLT2i across entire ejection fraction range

News - Aug. 27, 2022

ESC 2022 A pooled analysis of DAPA-HF and DELIVER was undertaken to examine the effect of dapagliflozin in patient with heart failure across the entire spectrum of ejection fraction.

Two meta-analyses support prioritizing use of SGLT2i in all HF patients

News - Aug. 27, 2022

Two meta-analyses were performed including SGLT2i trials in HF patients: one including DELIVER and EMPEROR-Preserved and the other one of the 5 trials DELIVER, EMPEROR-Preserved, DAPA-HF, EMPEROR-Reduced and SOLOIST-WHF.